Intact Investment Management Inc. Has $634,000 Holdings in Humana Inc. (NYSE:HUM)

Intact Investment Management Inc. lessened its holdings in shares of Humana Inc. (NYSE:HUM) by 10.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,500 shares of the insurance provider’s stock after selling 280 shares during the quarter. Intact Investment Management Inc.’s holdings in Humana were worth $634,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. FPC Investment Advisory Inc. acquired a new stake in shares of Humana in the 4th quarter valued at about $27,000. Centricity Wealth Management LLC acquired a new stake in shares of Humana in the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA raised its stake in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Humana in the 4th quarter valued at about $33,000. Finally, Atwood & Palmer Inc. raised its stake in shares of Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after purchasing an additional 60 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Trading Up 0.5 %

Shares of NYSE:HUM opened at $253.11 on Friday. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The stock has a market cap of $30.55 billion, a PE ratio of 25.44, a P/E/G ratio of 2.05 and a beta of 0.57. The business has a 50 day moving average of $271.37 and a 200-day moving average of $280.01. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last issued its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.40%. Humana’s payout ratio is 35.58%.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Morgan Stanley dropped their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Piper Sandler raised their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Barclays raised their price objective on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. Royal Bank of Canada restated an “outperform” rating and issued a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. decreased their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Humana has an average rating of “Hold” and a consensus price target of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.